Navigation Links
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Date:10/13/2008

'New Class' of Stent with Polyzene(R)-F Surface Treatment Maximizes Endothelialization; Reduces Restenosis, Thrombogenicity, Need for Long-Term Dual Antiplatelet Therapy

WASHINGTON, Oct. 13 /PRNewswire/ -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA(TM) stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
5. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
6. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
7. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
9. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the ... and good people, all for a good cause. In its second year, the “Music ... more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug status ... any time soon, according to educational website Surviving Mesothelioma. Click here to read ... designation for mesothelioma last week from the FDA, will now head into Phase I ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... is pleased to welcome TJS Insurance Group as its newest Partner Firm. Founded ... guides them and keeps them focused on their goals. Within the past 10 ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... savings comes an extra,hour of sleep, but how ... to the daily cup of coffee, early birds ... the Flower Promotion Organization at:, http://media.medialink.com/WebNR.aspx?story=34055 ) ... that study participants reported being happier and more ...
... Stryker Corporation,(NYSE: SYK ) announced today that it will participate in the ... 8:30 a.m. Mountain Standard Time Credit ... November 27, 2007 - 12:30 p.m. ... Care Conference New York, New York ...
... University Class Tests Benefits of Chewing Gum During Exam, ... can,be particularly stressful on college students as they struggle ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071101/AQTH193 ) "It,s common practice ... and pull all-nighters in preparation for exams," says Adrinda,Kelly, ...
... Centers, Inc.,("GNC" or the "Company"), announced today that it ... third quarter 2007 financial,results at 11 a.m. EST Thursday, ... the U.S., dial 1-888-895-5479, and,outside the U.S. dial 1-847-619-6250. ... webcast of the call will also be available,through the ...
... awards,Ashaway,s horse-assisted rehabilitative therapy with Premier Center Program ... ... Nov. 1 Turning Pointe,Therapeutic Riding has again been recognized ... the Handicapped Association (NARHA),the national standard bearer for therapeutic equine ...
... Kids,Indiana Action Fund launched an independent, direct ... supporting local elected officials who,have championed smoke-free ... - D) and Scott Keller (District 16 ... in passing Indianapolis, smoke-free,ordinance. The Indianapolis smoke-free ...
Cached Medicine News:Health News:Stryker to Present at Investor Conferences 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 3Health News:As Exams Loom, Students Find Hope in a 'Stick' 4Health News:Turning Pointe Therapeutic Riding Recognized for Excellence in Providing Equine-Assisted Therapies to People with Disabilities 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: